Macrolides for the long-term management of asthma - A meta-analysis of randomized clinical trials

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 8, 2013, Pages 1040-1049

  Reiter, J ^a   Demirel, N ^a   Mendy, A ^b   Gasana, J ^c   Vieira, E R ^d   Colin, A A ^a   Quizon, A ^a   Forno, E ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c South Florida Asthma Consortium   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

anti asthmatic agents; asthma; macrolides; meta analysis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; ROXITHROMYCIN; TROLEANDOMYCIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ARTICLE; ASTHMA; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; LUNG FUNCTION; META ANALYSIS; NAUSEA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; SWELLING; TREATMENT DURATION; VERTIGO; VOMITING;

ANTI-ASTHMATIC AGENTS; ASTHMA; MACROLIDES; META-ANALYSIS;

ADULT; ASTHMA; BRONCHIAL HYPERREACTIVITY; CHILD; FEASIBILITY STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MACROLIDES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 84883141957     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12199     Document Type: Article

References (49)

1. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758-766.
2. Johnston SL,. Macrolide antibiotics and asthma treatment. J Allergy Clin Immunol 2006; 117: 1233-1236.
3. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2012. Available at: http://www.ginasthma.org/.
4. Louis R, Schleich F, Barnes PJ,. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012; 33: 531-541.
5. Spagnolo P, Fabbri LM, Bush A,. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2012; doi: 10.1183/09031936.00136712. [Epub ahead of print.]
6. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP,. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61: 895-902.
7. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M,. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-1832.
8. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA,. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
9. Benden C, Boehler A,. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009; 87: 1538-1540.
10. Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006; 31: 49-55.
11. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH,. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001; 107: 595-601.
12. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG,. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005; 19: CD002997.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Haynes RB,. Conducting Systematic Reviews. In:, Haynes RB, Sacket LD, Guyatt HG, Tugwell P, editors. Clinical epidemiology: how to do clinical practice research. Philadelphia, PA: Lippincott Williams & Wilkins, 2006: 15-42.
15. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J,. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193-206.
16. Lau J, Ioannidis JP, Schmid CH,. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
17. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84: 594-598.
18. Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164: 536-541.
19. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329.
20. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004; 23: 714-717.
21. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings 2007; 28: 194-198.
22. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG,. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148-155.
23. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126: 747-753.
24. Kamada AK, Hill MR, Ikle DN, Brenner AM, Szefler SJ,. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91: 873-882.
25. Hahn DL, Grasmick M, Hetzel S, Yale S, Group AS,. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med 2012; 25: 442-459.
26. Hahn DL, Plane MB, Mahdi OS, Byrne GI,. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006; 1: e11.
27. Kraft M, Cassell GH, Pak J, Martin RJ,. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121: 1782-1788.
28. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H,. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999; 29: 950-956.
29. WHO. Asthma, Fact sheet N 307. 2011. Available at: http://www.who.int/ mediacentre/factsheets/fs307/en/index.html.
30. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120: S94-S138.
31. Hanania NA,. Targeting airway inflammation in asthma: current and future therapies. Chest 2008; 133: 989-998.
32. Chipps BE, Zeiger RS, Dorenbaum A, Borish L, Wenzel SE, Miller DP, et al. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep 2012; 1: 259-269.
33. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG,. Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms. Respiration 2011; 81: 67-74.
34. Friedlander AL, Albert RK,. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-1212.
35. Itkin IH, Menzel ML,. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45: 146-162.
36. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354: 1589-1600.
37. Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008; 122: 1138-1144. e1134
38. Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, et al. Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res Clin Exp 2004; 65: 1-12.
39. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA,. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004; 170: 426-432.
40. van Dalen C, Harding E, Parkin J, Cheng S, Pearce N, Douwes J,. Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents. Arch Pediatr Adolesc Med 2008; 162: 1169-1174.
41. Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H, Jinnai M, et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009; 22: 326-332.
42. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
43. Brannan JD,. Bronchial hyperresponsiveness in the assessment of asthma control: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138: 11S-17S.
44. Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009; 136: 498-506.
45. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM,. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1890.
46. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S,. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368: 1665-1668.
47. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-360.
48. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
49. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.